A budget impact model for paclitaxel-eluting stent in femoropopliteal disease in France

CardioVascular and Interventional Radiology

Volumn 36, Issue 2, 2013, Pages 362-370

  De Cock, Erwin ^a   Sapoval, Marc ^b   Julia, Pierre ^b   De Lissovoy, Greg ^c   Lopes, Sandra ^d  

^a United BioSource Corporation   (Spain)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d Cook Medical ^*  (Denmark)

Author keywords

Budget impact model; Drug eluting stent; Paclitaxel eluting stent; Peripheral artery disease; Superficial femoral artery

Indexed keywords

PACLITAXEL;

ARTICLE; BARE METAL STENT; BUDGET; CARDIOVASCULAR PROCEDURE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG ELUTING STENT; FEMOROPOPLITEAL DISEASE; FRANCE; HUMAN; LEG REVASCULARIZATION; MAJOR CLINICAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REIMBURSEMENT; RETREATMENT; THERAPY EFFECT;

ARTERIAL OCCLUSIVE DISEASES; ATHEROSCLEROSIS; BUDGETS; DRUG-ELUTING STENTS; FEMORAL ARTERY; FRANCE; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; PACLITAXEL; PERIPHERAL VASCULAR DISEASES; POPLITEAL ARTERY;

EID: 84875224548     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-012-0494-x     Document Type: Article

References (36)

1. Norgren L, Hiatt WR, Dormandy JA et al (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 33(Suppl 1):S1-S75
2. Mahoney EM, Wang K, Keo HH et al (2010) Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circ Cardiovasc Qual Outcomes 3:642-651
3. Gey DC, Lesho EP, Manngold J (2004) Management of peripheral arterial disease. Am Fam Physician 69:525-532
4. Hankey GJ, Norman PE, Eikelboom JW (2006) Medical treatment of peripheral arterial disease. JAMA 295:547-553
5. Hernandez-Vila EA (2011) Peripheral arterial disease in women: the effect of gender on diagnosis and treatment. Tex Heart Inst J 38:154-156
6. Steg PG, Bhatt DL, Wilson PW et al (2007) One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297:1197-1206
7. Adam DJ, Beard JD, Cleveland T et al (2005) Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL): multicentre, randomised controlled trial. Lancet 366(9501):1925-1934
8. Gable D (2011) Role of total endoluminal superficial femoral artery bypass. J Cardiovasc Surg (Torino) 52:683-700
9. Schillinger M, Sabeti S, Loewe C et al (2006) Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 354:1879-1888
10. Bosiers M, Torsello G, Gissler HM et al (2009) Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther 16:261-269
11. Krankenberg H, Schluter M, Steinkamp HJ et al (2007) Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST). Circulation 116:285-292
12. Laird JR, Katzen BT, Scheinert D et al (2010) Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 3:267-276
13. Dake MD, Ansel GM, Jaff MR et al (2011) Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 4:495-504
14. Gray WA (2010) Two-year interim results from the single-arm clinical study of the Zilver PTX drug-eluting stent. Paper presented at society for cardiovascular angiography and interventions 33rd annual scientific sessions, San Diego, CA
15. Dake MD, Scheinert D, Tepe G et al (2011) Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther 18:613-623
16. Ministère du travail, de l'emploi et de la santé (2011) Arrêté du 6 septembre 2011 relatif à l'inscription de l'endoprothèse périphérique à libération de principe actif (paclitaxel) ZILVER PTX de la société COOK France au chapitre 1er du titre III de la liste des produits et prestations remboursables prévue à l'article L. 165-1 du code de la sécurité sociale. Journal officiel de la République française (JORF) no 27. Paris, France. http://www.legifrance.gouv.fr/ affichTexte.do;jsessionid=63ED0A58C70AA651A071D9BC7CDC4371.tpdjo11v-2?cidTexte= JORFTEXT000024543595&dateTexte=&oldAction=rechJO&categorieLien=id. Accessed 14 Sep 2011
17. Agence Technique de l'Information sur l'Hospitalisation (2012) Statistiques en ligne issues de la base nationale PMSI-MCO Agence Technique de l'Information sur l'Hospitalisation. Lyon, France. http://www.atih.sante.fr/ index.php?id=0004400001FF. Accessed 23 Aug 2011
18. Haute Autorité de Santé, Avis de la Commission Nationale d'Evaluation des Dispositifs Médicaux et des Technologies de Santé (CNEDiMTS) (2010) ZILVER PTX, endoprothèse périphérique à libération de principe actif (paclitaxel). Haute Autorité de Santé. Saint-Denis La Plaine, France. http://www.has-sante.fr/ portail/jcms/c-996539/zilver-ptx-09-novembre-2010-2807-avis?xtmc= zilver&xtcr=1. Accessed 22 Aug 2011
19. Katzen B, Laird J (2008) RESILIENT data: 1-year final results. Paper presented at 2008 international symposium on endovascular therapy (ISET-2008), Hollywood, FL
20. Katzen BT (2008) Update and new findings from the RESILIENT trial comparing the (Bard) Lifestent with POBA: is the improvement with stenting durable beyond 1 year? Paper presented at 35th annual VEITH symposium, New York, NY
21. Bradbury AW, Adam DJ, Bell J et al (2010) Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial. Health Technol Assess 14:1-210, iii-iv
22. Ministère du travail, de l'emploi et de la santé (2011) Arrêté du 1er mars 2011 fixant pour l'année 2011 les éléments tarifaires mentionnés aux I et IV de l'article L. 162-22-10 du code de la sécurité sociale et aux IV et V de l'article 33 modifié de la loi de financement de la sé curité sociale pour 2004. Journal officiel de la République française (JORF) no 15. Paris, France. http://www.legifrance.gouv.fr/ affichTexte.do;jsessionid=63ED0A58C70AA651A071D9BC7CDC4371.tpdjo11v-2?cidTexte= JORFTEXT000023651050&dateTexte=&oldAction=rechJO&categorieLien=id. Accessed 26 Aug 2011
23. Ministère du travail, de l'emploi et de la santé (2011) Avis relatif aux tarifs et aux prix limites de vente au public en euros TTC d'un produit visé à l'article L. 165-1 du code de la sécurité sociale. Journal officiel de la République française (JORF) no 101. Paris, France. http://www.legifrance.gouv.fr/ affichTexte.do;jsessionid=63ED0A58C70AA651A071D9BC7CDC4371.tpdjo11v-2?cidTexte= JORFTEXT000024543909&dateTexte=&oldAction=rechJO&categorieLien=id/. Accessed 14 Sep 2011
24. Sécurité Sociale - l'Assurance Maladie (2011) Gestion Risques Maladie. Liste des produits et prestations. Securité Sociale-l'Assurance Maladie. Paris, France. http://www.codage.ext.cnamts.fr/cgi/ tips/cgi-fiche?p-code-tips=3183194&p-date-jo-arrete=%25&p-menu= FICHE&p-site=. Accessed 29 Aug 2011
25. Sécurité Sociale-l'Assurance Maladie (2011) Gestion Risques Maladie. Liste des produits et prestations. Securité Sociale-l'Assurance Maladie. Paris, France. http://www.codage.ext.cnamts.fr/codif/tips//chapitre/ index-chap.php?p-ref-menu-code=552&p-site=. Accessed 29 Aug 2011
26. Sécurité Sociale-l'Assurance Maladie (2011) Classification Commune des Actes Médicaux (CCAM) en ligne. La Caisse nationale de l'Assurance Maladie des travailleurs salariés (CNAMTS). Paris, France. http://www.ameli.fr/accueil-de-la-ccam/index.php. Accessed 29 Aug 2011
27. Mauskopf JA, Sullivan SD, Annemans L et al (2007) Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices-budget impact analysis. Value Health 10:336-347
28. Stoner MC, Defreitas DJ, Manwaring MM et al (2008) Cost per day of patency: understanding the impact of patency and reintervention in a sustainable model of healthcare. J Vasc Surg 48:1489-1496
29. Bosiers M, Deloose K, Keirse K, Verbist J, Peeters P (2010) Are drug-eluting stents the future of SFA treatment? J Cardiovasc Surg (Torino) 51:115-119
30. Bosiers M, Deloose K, Callaert J et al (2011) Results of the Protege EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg 54:1042-1050
31. Dick P, Sabeti S, Mlekusch W et al (2008) Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology 248:297-302
32. Sabeti S, Mlekusch W, Amighi J, Minar E, Schillinger M (2005) Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther 12:6-12
33. Zeller T, Macharzina R, Tepe G (2010) The potential role of DES in peripheral in-stent restenosis. J Cardiovasc Surg (Torino) 51:561-565
34. Scheinert D (2010) Drug-eluting balloons in the SFA. Endovasc Today (March):42-44
35. Ansel G (2011) Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease: 24-month update. Paper presented at CRT 2011, Washington, DC
36. Laird JR, Katzen BT, Scheinert D et al (2012) Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther 19:1-9